Track Kodiak Sciences Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Kodiak Sciences Inc. KOD · Stock Open Kodiak Sciences Inc. in new tab

111.19 USD
EPS
-4.19
P/B
110.94
ROE
-368.37
Beta
1.98
Target Price
121.67 USD
Loading chart...
Key Metrics
Earnings dateMarch 30, 2027
EPS-4.19
Book Value0.97
Price to Book110.94
Debt/Equity86.35
% Insiders5.161%
Estimates
Forward P/E-31.45
Forward EPS-3.44
Target Mean Price121.67

DCF valuation

Model fair value for Kodiak Sciences Inc. (KOD)
Result
Sign in to run the valuation for KOD.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
6 analysts · consensus None · mean target 121.67 USD (low 103.00, high 145.00) · as of 11 Nov 2026
Low 103.00
Mean 121.67
High 145.00
Price 111.19
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Kodiak Sciences Inc. Logo Kodiak Sciences Inc. Analysis (KOD)

United States Health Care Official Website Stock

Is Kodiak Sciences Inc. a good investment? Kodiak Sciences Inc. (KOD) is currently trading at 111.19 USD. Market analysts have a consensus price target of 121.67 USD. This suggests a potential upside from current levels.

Earnings Schedule: Kodiak Sciences Inc. is expected to release its next earnings report on March 30, 2027. The market consensus estimate for Forward EPS is -3.44.

Investor FAQ

Does Kodiak Sciences Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Kodiak Sciences Inc.?

Kodiak Sciences Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 30, 2027. The company currently has a trailing EPS of -4.19.

Company Profile

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Exchange Ticker
NMS (United States) KOD
FRA (Germany) K27.F
MEX (Mexico) KOD.MX
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Feb. 23, 2022 5:1
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion